Gsa Capital Partners LLP Cel Sci Corp Transaction History
Gsa Capital Partners LLP
- $1.35 Billion
- Q4 2024
A detailed history of Gsa Capital Partners LLP transactions in Cel Sci Corp stock. As of the latest transaction made, Gsa Capital Partners LLP holds 45,745 shares of CVM stock, worth $19,212. This represents 0.0% of its overall portfolio holdings.
Number of Shares
45,745Holding current value
$19,212% of portfolio
0.0%Shares
11 transactions
Others Institutions Holding CVM
# of Institutions
72Shares Held
6.95MCall Options Held
38.3KPut Options Held
184K-
Vanguard Group Inc Valley Forge, PA2.37MShares$995,6460.0% of portfolio
-
Black Rock Inc. New York, NY775KShares$325,3750.0% of portfolio
-
Sabby Management, LLC Upper Saddle River, NJ712KShares$298,9282.94% of portfolio
-
Geode Capital Management, LLC Boston, MA572KShares$240,4430.0% of portfolio
-
Advisor Group Holdings, Inc. Phoenix, AZ432KShares$181,4930.0% of portfolio
About CEL SCI CORP
- Ticker CVM
- Exchange NYSE
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 43,367,500
- Market Cap $18.2M
- Description
- CEL-SCI Corporation engages in the research and development of immunotherapy for the treatment of cancer and infectious diseases. The company's lead investigational immunotherapy is Multikine, which is under phase III clinical trial for the treatment of head and neck cancer. Its Ligand Epitope Antigen Presentation System (LEAPS), a pre-clinical ...